相关实验视频
Updated: May 6, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
通过每月校准的光电显微镜和隐性HbA1c改进非侵入性葡萄糖估计
Justin Chu1,2, Tung-Han Hsieh1, Yao-Ting Chang3
1Research Center for Applied Sciences, Academia Sinica, Taipei City, Taiwan, ROC.
Communications medicine
|December 24, 2025
概括
每月一次的预测测试允许对不同糖尿病患者群体进行准确的,非侵入性的血糖监测. 这种可穿戴技术简化了管理,并加强了公共卫生预防工作.
科学领域:
- 生物医学工程 生物医学工程
- 医疗器械 医疗器械
- 糖尿病 技术 技术
背景情况:
- 目前的非侵入性血糖监测,特别是使用光电显微镜 (PPG) 的可穿戴设备,需要经常重新校准,并且仅限于特定的患者队列.
- 现有的方法在各种患者群体的准确性和广泛适用性方面面临挑战,包括那些有不同的药物治疗方案的患者.
研究的目的:
- 评估单个月度预测测试的可行性,以实现非侵入性血糖测量的临床准确性.
- 通过开发特定队列模型,扩大非侵入性葡萄糖监测的适用性.
主要方法:
- 基于抗糖尿病药物使用的三个不同患者组开发了预测模型:没有,仅用口服,以及组合治疗.
- 训练模型使用月度预测和不使用月度预测的队列数据,允许直接应用到个人测试中,无需重新培训.
- 利用双通道PPG信号和推断的糖化血红蛋白 (HbA1c) 特性,通过使用帕克斯误差网来评估平均绝对相对差异和临床安全的准确性.
主要成果:
- 这三组患者的平均绝对相对差异分别为9.59%,12.23%和16.40%,使用单个月前测试.
- 与以前的研究相比,在最复杂的患者组 (组合疗法) 中,预测错误明显较低.
- 确保帕克斯误差网上没有临床上不可接受的读数,归因于双通道输入和推断的HbA1c特征.
结论:
- 一个单个月的预测测试可以在不同患者群体中进行准确和临床安全的非侵入性血糖监测.
- 拟议的方法不需要再培训或微调,并支持将其整合到目前用于糖尿病管理和公共卫生的可穿戴设备中.
- 边缘计算能够适应新用户和新设备,为日常糖尿病护理中的广泛采用铺平了道路.
更多相关视频
08:01A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
Published on: August 12, 2016
9.4K
04:54Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans
Published on: June 2, 2023
1.9K
相关概念视频
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
32
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
32
Hyperglycemia
35
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
35